/** PI Industries Q4 FY26 */

PI Industries Q4 FY26: Managing the Downcycle, Funding the Next Growth Curve

PI Industries ended Q4 FY26 with a clear message: the global agrochemical cycle stayed volatile, but the company focused on preserving margins and continuing investment in its next set of growth platforms. Consolidated revenue for Q4 FY26 was INR 1,565.2 crore, down 12% year-on-year. EBITDA was INR 337.3 crore, down 26%, and profit after tax including exceptional items was INR 200.2 crore, down 39%.

For the full year, the downcycle impact was sharper on topline. FY26 consolidated revenue was INR 6,713.7 crore, down 16% from FY25. EBITDA was INR 1,705.3 crore, down 22%, while PAT including exceptional items declined 20% to INR 1,320.8 crore. Yet PI highlighted resilience in profitability: gross margin expanded to 58% for both Q4 and FY26, and FY26 EBITDA margin came in at 25%, which management said was in line with the guidance given at the start of the year.

The earnings call repeatedly returned to the same operating reality. Customers moved further toward just-in-time procurement, the global agrochemical recovery remained uneven, and fresh disruptions emerged from geopolitical events. In that context, PI’s approach was to defend quality of earnings, protect market share, and keep funding its longer-gestation bets.

Export and domestic performance: volumes, mix, and inventory pressure

The export business remained the main drag. In Q4 FY26, exports were INR 1,258.5 crore versus INR 1,448.8 crore in Q4 FY25. Management attributed the decline primarily to lower volumes in line with the broader global contraction and shifting delivery schedules. For FY26, exports fell to INR 5,411.7 crore from INR 6,579.4 crore.

Domestic performance was also subdued, but for different reasons. Q4 domestic revenue was INR 306.7 crore, down 9% year-on-year, even as management indicated volumes were up about 3%. The company pointed to elevated channel inventory, pricing pressure, reduction in key crop acreages, and regulatory transitions in biologics. For FY26, domestic revenue declined to INR 1,302.0 crore from INR 1,398.4 crore.

Where PI attempted to show progress was on the portfolio refresh. The investor presentation said the company commercialised 5 new molecules in exports and launched 4 products in domestic agri brands during FY26. It also disclosed that new products contributed 18% of agchem exports revenue in FY26, positioning this as a de-risking lever during a difficult industry year.

Pharma and biologicals: traction, but still early in the curve

PI’s diversification narrative was led by two areas: pharma under PI Health Sciences and global biologicals.

Pharma recorded its highest quarterly sales for FY26, with Q4 FY26 revenue at INR 104.8 crore, up 23% year-on-year. For FY26, pharma revenue grew 40% to INR 300.5 crore. However, profitability remained negative at the PBT level. FY26 pharma PBT was a loss of INR 78.5 crore, though improved from the FY25 loss.

Management emphasized capability build rather than near-term margins. The company discussed filing for regulatory approval of a GMP kilo facility in Lodi, Italy, adding a drug discovery center of excellence at its Hyderabad CRO, setting up a state-of-the-art QC lab in Lodi, and expanding CADD and ML toolkits for large library screening. On the call, management stated an aspiration for the pharma platform to reach INR 500 to INR 600 crore of topline in the next two to three years and to start moving toward positive EBITDA.

Global biologicals were presented as a higher-margin, scalable opportunity, but still in investment mode. The presentation stated that global biologicals ex-India have an annualized revenue of about USD 12 million with margins upward of 60%, expected to grow in double digits. During the call, management highlighted that a biological nematode product received US EPA registration. They described it as a unique foliar-applied offering and said the product is already launched in Brazil and Mexico, with the US as the third market. Management also cautioned that farmer adoption in biologicals takes time and indicated it may take a couple of years to establish the product.

Cash, capex, and the question of returns

PI’s balance sheet continued to be a central pillar of the investment narrative. The company reported surplus cash net of debt of INR 3,426.5 crore, which management positioned as strategic flexibility for future investments. Operating cash flow for FY26 was INR 474.0 crore.

Capex remained elevated even as revenues declined. FY26 capex was INR 1,150.8 crore, up from INR 928.0 crore in FY25. On the call, management guided FY27 capex at INR 700 to INR 800 crore. Investors pressed management on asset turns and capex conversion. The response was that ramp-up for new molecule capacities is multi-year, and that a part of recent spending has gone toward technology, the in-house NCE program, and newer business arenas with longer gestation.

One operational datapoint provided was capacity utilisation, which management said was around 80% for FY26. Working capital was also discussed. Net working capital days were stated at 139 days, with inventory days improving sequentially but payables days declining.

Tax rates were flagged as a moving part. Management said the effective tax rate for FY26 was about 22%, and guided that it could inch up to about 24% in FY27 and beyond due to a higher share of non-SEZ business.

FY27: growth expected, but with a cautious posture

The outlook statements were directionally positive but carefully worded. Management said it expects FY27 to deliver growth, supported by exports and global biologicals gaining traction, and domestic benefiting from new brand launches. It also stated cautious optimism for H2 FY27 on the back of committed customer off-take plans and a strong order book. On the call, management mentioned an order book of about USD 1.0 to 1.2 billion, without a segment-wise breakup.

PI also reiterated progress on its in-house innovation agenda. The first NCE, Pioxaniliprole, was described as filed for registration and expected to be launched in FY27. Management said it intends to file in select overseas geographies by end of the year or next year, and that global commercialization would likely involve strategic partnerships.

The overall tone was realistic about external uncertainty. Management repeatedly referred to volatility in raw material availability and input costs, and the difficulty of giving precise margin guidance in the current environment. However, it maintained that the company would aim to sustain average gross margins at FY26 levels while continuing investments for long-term trajectory.

Takeaways

PI Industries’ FY26 numbers reflect a cyclical downturn in its core export-driven agchem business, but the company protected margins through mix and cost discipline. The balance sheet strength, net cash of INR 3,426.5 crore, and continued capex point to management’s intention to invest through the cycle. FY27 will be watched for three proof points: export recovery in the second half, scale-up progress in pharma toward the INR 500 to INR 600 crore target over two to three years, and whether global biologicals can convert registrations into sustained growth while moving toward break-even over the next couple of years.